Overview

* Immunome ( IMNM ) reports Q3 net loss of $57.5 mln,

* Company holds $272.6 mln in cash as of September 30, 2025, funding operations into 2027

* Research and development expenses for Q3 were $49.2 mln

Outlook

* Varegacestat

Immunomeexpectsto report topline data for the Phase 3 RINGSIDE Part B study before the end of 2025

* Immunome ( IMNM ) expects current cash to fund operations into 2027

Result Drivers

* R&D INVESTMENT - Significant investment in R&D with expenses totaling $49.2 mln for Q3

*

General and administrative expenses for the quarter ended September 30, 2025 were $10.9 million

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$57.46

Income mln

Q3 -$60.14

Income mln

From

Operatio

ns

Q3 $60.14

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Immunome Inc ( IMNM ) is $23.50, about 34.7% above its November 5 closing price of $15.35

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)